CRL Charles River Laboratories International Inc.

Charles River Laboratories to Participate in Jefferies and William Blair Conferences

WILMINGTON, Mass.--(BUSINESS WIRE)--

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2nd, at 10:00 a.m. ET, and at the William Blair 40th Annual Growth Stock Conference on Tuesday, June 9th, at 10:00 a.m. CT (11:00 a.m. ET). Management will present an overview of Charles River’s strategic focus and business developments.

A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at . A webcast replay will be accessible through the same website after each presentation and will remain available for approximately two weeks.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit .

###

EN
01/06/2020

Underlying

CRLCharles River Laboratories International Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Charles River Laboratories International Inc.

 PRESS RELEASE
Free
CRL Charles River L...

Charles River Laboratories Launches Alternative Methods Advancement Pr...

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing alternatives to reduce animal testing. The initiative aims to drive the new standard for drug discovery and development and encapsulates the Company’s initial $200 million investment over the past four years and its five-year goal of investing an additional $300 million. This investment spans a portfolio of technology innovations, partnerships, and advocacy efforts to reduce...

April 16, 2024 1 EN
 PRESS RELEASE
Free
CRL Charles River L...

Charles River Laboratories Schedules First-Quarter 2024 Earnings Relea...

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 9th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at . A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharma...

April 12, 2024 1 EN
 PRESS RELEASE
Free
CRL Charles River L...

Charles River and Deciphex Launch Patholytix Foresight, a Transformati...

WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology AI. By combining Deciphex’s unique digital pathology solutions with Charles River’s robust non-clinical pathology programs, clients of both organizations will have access to the technology-driven capabilities to accelerate primary evaluation and peer review in toxicologic pathology assessment, enhancing deci...

April 11, 2024 1 EN
 PRESS RELEASE
Free
CRL Charles River L...

Charles River Announces Rare Disease Gene Therapy Collaboration with A...

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with . Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure. Ciliopathies are diseases caused by cilia dysfunction, which is a group of complex disorders caused by genetic mutations that result in defective or dy...

April 9, 2024 1 EN
 PRESS RELEASE
Free
CRL Charles River L...

Charles River to Perform Plasmid Production for Ship of Theseus

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) and , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement. Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate. Ship of Theseus is developing a proprietary suite of biologics based on the HOX family of transcription factors, wh...

April 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch